The association between MDR1 C3435T genetic polymorphism and the risk of multidrug-resistant epilepsy in Egyptian children

Egyptian Journal of Medical Human Genetics

Table 8 Relation between MDR1 C3435T SNP and epilepsy drugs used

Drug	*MDR1* C3435T genotype			χ²	p
Drug	CC, n = 50 (%)	CT, n = 41 (%)	TT, n = 15 (%)	χ²	p
Sodium valproate	41 (82.0)	39 (95.1)	15 (100)	6.2	0.04*
Carbamazepine	11 (22.0)	8 (19.5)	3 (20.0)	0.09	0.95
Leviteracetam	28 (56.0)	23 (56.1)	10 (66.7)	0.59	0.74
Oxacarbamazepine	8 (16.0)	5 (12.2)	3 (20.0)	0.58	0.74
Topiramate	19 (38.0)	12 (29.3)	5 (33.3)	0.77	0.68
Clonazepam	6 (12.0)	5 (12.2)	4 (26.7)	2.3	0.32
Phenytoin	4 (8.0)	0 (0.0)	0 (0.0)	4.7	0.1
Lacosamide	1 (2.0)	0 (0.0)	0 (0.0)	1.1	0.57
Lamotrigine	1 (2.0)	2 (4.9)	1 (6.7)	0.92	0.63

The only statistically significant association between drug type and genotype distribution for the cases maintained on sodium valproate and MDR1 C3435T genotype distribution with 100% of genotype TT variant had resistance followed by CT genotype and CC (value = 0.04*). Non-statistically significant association was found between MDR1 C3435T genetic polymorphism and many antiepileptic drugs (carbamazepine, levetiracetam, oxacarbamazepine, topiramate, clonazepam, phenytoin, lacosamide, and lamotrigine); p value> 0.05